Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults

NCT01450579 is registered in ClinicalTrials.gov with UMN Pharma Inc. as lead sponsor.

NCT NCT01450579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01450579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults
Lead sponsor
UMN Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2011
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy